Literature DB >> 16918888

Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial.

B D Ye1, J H Cheon, K D Choi, S G Kim, J S Kim, H C Jung, I S Song.   

Abstract

BACKGROUND: Acid suppressing agents are widely used to treat the iatrogenic ulcers following endoscopic mucosal resection for gastric neoplasms. However, the relative merits of proton pump inhibitor or histamine(2)-receptor antagonist for endoscopic mucosal resection-induced ulcers are not known. AIM: To prospectively compare omeprazole and famotidine for the healing of endoscopic mucosal resection-induced ulcers and for bleeding control.
METHODS: After endoscopic mucosal resection, patients were randomly assigned to omeprazole (20 mg/day) or to famotidine (40 mg/day) group for a 28-day treatment period. The ulcer sizes and stages, bleeding rates and ulcer-related symptoms were compared.
RESULTS: A total of 100 patients were randomized equally to each group. Forty-one patients in each group were finally compared. The two groups were comparable in terms of baseline characteristics. Twenty-eight days after treatment, the two groups were not different with respect to ulcer stage (P = 0.137) or ulcer reduction ratio (P = 0.380). No difference was observed with respect to ulcer-related symptoms (P = 0.437) and no bleeding episode occurred in any of the 82 patients. In subgroup that underwent endoscopic submucosal dissection, fewer patients in the omeprazole group showed active ulcers than those in the famotidine group (P = 0.035).
CONCLUSION: Our results demonstrate that omeprazole may be superior to famotidine for iatrogenic ulcers following endoscopic mucosal resection, especially for large ulcers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918888     DOI: 10.1111/j.1365-2036.2006.03050.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  25 in total

1.  Optimal duration of proton pump inhibitor for healing artificial ulcers after endoscopic submucosal dissection for early gastric cancer.

Authors:  Takuji Gotoda
Journal:  Dig Dis Sci       Date:  2011-12-25       Impact factor: 3.199

2.  Comparison of the efficacy of 4- and 8-week lansoprazole treatment for ESD-induced gastric ulcers: a randomized, prospective, controlled study.

Authors:  Ji Hoon Park; Eun Kyung Baek; Chang Hwan Choi; Kyung Hun Lee; Beom Jin Kim; Jeong Wook Kim; Jae Gyu Kim; Sae Kyung Chang
Journal:  Surg Endosc       Date:  2013-08-31       Impact factor: 4.584

3.  Optimal duration of proton pump inhibitor in the treatment of endoscopic submucosal dissection-induced ulcers: a retrospective analysis and prospective validation study.

Authors:  Suck-Ho Lee; Chang Kyun Lee; Il-Kwun Chung; Yun Suk Shim; Tae Hoon Lee; Sae Hwan Lee; Hong-Soo Kim; Sang-Heum Park; Sun-Joo Kim
Journal:  Dig Dis Sci       Date:  2011-10-15       Impact factor: 3.199

Review 4.  Proton pump inhibitors therapy vs H2 receptor antagonists therapy for upper gastrointestinal bleeding after endoscopy: A meta-analysis.

Authors:  Ying-Shi Zhang; Qing Li; Bo-Sai He; Ran Liu; Zuo-Jing Li
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

5.  High Dose Proton Pump Inhibitor Infusion Versus Bolus Injection for the Prevention of Bleeding After Endoscopic Submucosal Dissection: Prospective Randomized Controlled Study.

Authors:  Cheol Woong Choi; Dae Hwan Kang; Hyung Wook Kim; Joung Boom Hong; Su Bum Park; Su Jin Kim; Mong Cho
Journal:  Dig Dis Sci       Date:  2015-03-28       Impact factor: 3.199

6.  Risk factors of delayed ulcer healing after gastric endoscopic submucosal dissection.

Authors:  Joo Hyun Lim; Sang Gyun Kim; Jeongmin Choi; Jong Pil Im; Joo Sung Kim; Hyun Chae Jung
Journal:  Surg Endosc       Date:  2015-03-05       Impact factor: 4.584

7.  Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia.

Authors:  Hiroyuki Imaeda; Naoki Hosoe; Hidekazu Suzuki; Yoshimasa Saito; Yosuke Ida; Rieko Nakamura; Yasushi Iwao; Haruhiko Ogata; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2011-07-30       Impact factor: 7.527

8.  Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection--a randomized controlled study.

Authors:  Tomohiro Kato; Hiroshi Araki; Fumito Onogi; Takashi Ibuka; Akihiko Sugiyama; Eiichi Tomita; Masahito Nagaki; Hisataka Moriwaki
Journal:  J Gastroenterol       Date:  2009-12-03       Impact factor: 7.527

9.  Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer.

Authors:  Hong Jun Park; Hyun-Soo Kim; Bo Ra Kim; So Yeon Park; Jin Heon Hong; Ki Won Jo; Jae Woo Kim
Journal:  Dig Dis Sci       Date:  2012-10-12       Impact factor: 3.199

10.  Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study.

Authors:  Yu Jin Kim; Jae Hee Cheon; Sang Kil Lee; Jie Hyun Kim; Yong Chan Lee
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.